122 related articles for article (PubMed ID: 28529212)
1. Exploring the Case for Eminent Domain of Hepatitis C Virus Treatment Patents.
Mattingly Ii TJ; Heil EL; Hoke KS
J Health Care Poor Underserved; 2017; 28(2):621-625. PubMed ID: 28529212
[TBL] [Abstract][Full Text] [Related]
2. Sovaldi dilemma likely to get worse.
Carroll J
Manag Care; 2014 Sep; 23(9):9, 12. PubMed ID: 25282860
[No Abstract] [Full Text] [Related]
3. Gilead injects own generics into shrinking HCV drug market.
Morrison C
Nat Biotechnol; 2018 Nov; 36(11):1030. PubMed ID: 30412188
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.
Chhatwal J; Kanwal F; Roberts MS; Dunn MA
Ann Intern Med; 2015 Mar; 162(6):397-406. PubMed ID: 25775312
[TBL] [Abstract][Full Text] [Related]
5. Take a Bow, Pharma, for the Hepatitis C Drugs.
Reinke T
Manag Care; 2018 Apr; 27(4):12-13. PubMed ID: 29701579
[TBL] [Abstract][Full Text] [Related]
6. New Hepatitis C Drugs Are Very Costly And Unavailable To Many State Prisoners.
Beckman AL; Bilinski A; Boyko R; Camp GM; Wall AT; Lim JK; Wang EA; Bruce RD; Gonsalves GS
Health Aff (Millwood); 2016 Oct; 35(10):1893-1901. PubMed ID: 27702964
[TBL] [Abstract][Full Text] [Related]
7. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.
Iyengar S; Tay-Teo K; Vogler S; Beyer P; Wiktor S; de Joncheere K; Hill S
PLoS Med; 2016 May; 13(5):e1002032. PubMed ID: 27243629
[TBL] [Abstract][Full Text] [Related]
8. [Not Available].
Springer Medizin
MMW Fortschr Med; 2016 Jul; 158(13):10-1. PubMed ID: 27439800
[No Abstract] [Full Text] [Related]
9. Drug pricing: still a barrier to elimination of HCV.
The Lancet Gastroenterology Hepatology
Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):813. PubMed ID: 30507462
[No Abstract] [Full Text] [Related]
10. Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients.
Chidi AP; Bryce CL; Donohue JM; Fine MJ; Landsittel DP; Myaskovsky L; Rogal SS; Switzer GE; Tsung A; Smith KJ
Value Health; 2016 Jun; 19(4):326-34. PubMed ID: 27325324
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.
Fraser I; Burger J; Lubbe M; Dranitsaris G; Sonderup M; Stander T
Pharmacoeconomics; 2016 Apr; 34(4):403-17. PubMed ID: 26666639
[TBL] [Abstract][Full Text] [Related]
12. Two Antiviral Drugs Approved For Adolescents With HCV.
Aschenbrenner DS
Am J Nurs; 2017 Aug; 117(8):22. PubMed ID: 28749879
[No Abstract] [Full Text] [Related]
13. Emerging options for treating hepatitis C infection.
Fantasia HC
Nurs Womens Health; 2015; 19(2):183-7. PubMed ID: 25900589
[TBL] [Abstract][Full Text] [Related]
14. New Indications for Harvoni.
Med Lett Drugs Ther; 2016 Jan; 58(1485):6. PubMed ID: 27099890
[No Abstract] [Full Text] [Related]
15. Hepatitis C drug maker puts profit ahead of patients, US Senate report charges.
McCarthy M
BMJ; 2015 Dec; 351():h6573. PubMed ID: 26635239
[No Abstract] [Full Text] [Related]
16. Evidence of HCV recovery after therapy of hepatitis C virus infection by direct acting antivirals.
Parlati L; Sirmai L; Dupuy CA; Glotz D; Pol S
Clin Res Hepatol Gastroenterol; 2019 Apr; 43(2):e18-e19. PubMed ID: 30293896
[No Abstract] [Full Text] [Related]
17. Modeling the fiscal costs and benefits of alternative treatment strategies in the United Kingdom for chronic hepatitis C.
Connolly MP; Kotsopoulos N; Ustianowski A
J Med Econ; 2018 Jan; 21(1):19-26. PubMed ID: 28830254
[TBL] [Abstract][Full Text] [Related]
18. Harvoni (ledipasvir and sofosbuvir) for hepatitis C.
Mullins C; Gibson W; Klibanov OM
Nurse Pract; 2015 Nov; 40(11):22-6. PubMed ID: 26474199
[No Abstract] [Full Text] [Related]
19. Role of Direct-Acting Antivirals in Hepatitis C Virus-Positive Castleman Disease.
Tahir M; Charles L
Am J Ther; 2018; 25(6):e733-e734. PubMed ID: 29557805
[No Abstract] [Full Text] [Related]
20. Guideline: New HCV drugs should go to sickest patients.
Kuehn BM
JAMA; 2014 Sep; 312(11):1084-5. PubMed ID: 25226461
[No Abstract] [Full Text] [Related]
[Next] [New Search]
